GHCL (GHCL)

Cyclical

FairStock Score: 53/100 — MIXED

Score breakdown: P/E: 3/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 1/1

Key Financials

Current Price₹429
Market Cap₹3,932.4 Cr
P/E Ratio7.66
ROCE24.19%
ROE16.16%
Dividend Yield2.8%
Profit Growth32.05%
Debt/Equity0.02
Sales Growth-3.06%
Promoter Holding19.83%
52-Week Range₹417.25 — ₹667.2
SectorChemicals & Petrochemicals
Book Value₹395.15

Strengths

Concerns

AI Analysis

Let me apply the Graham test to GHCL. A commodity chemical company at ₹502 with a market cap of ₹4,405 Cr. On the surface, the valuation looks cheap—P/E of 8.69 and P/B of 1.44 against book value of ₹349.93. But cheapness must be judged against earnings power and balance sheet. The company has a fortress-like debt profile: D/E of 0.03 and ROCE of 24.19%, suggesting capital allocation has been prudent. ROE of 16.16% is respectable. Yet the current year tells a different story: sales fell 2.85% and profits fell 37.06%. That is not the signature of a business with pricing power; it is the signature of a commodity cyclical. The latest quarter showed net profit of ₹106 Cr on sales of ₹757 Cr, so the operating engine is still working, but the trend is deteriorating. Graham would demand margin of safety. At 8.69 times earnings and 1.44 times book, the market is already offering a discount. However, the Piotroski F-score of 3/9 is a red flag—it signals weak fundamental health and deteriorating profitability. With promoter holding at only 19.83%, minority owners like me must also think about alignment; I prefer owners who eat their own cooking. The 2.50% dividend gives some compensation while waiting, but a falling earnings stream can make a low P/E into a value trap. I would not call GHCL a stalwart. This is a cyclical business, and the cycle is currently against it. The absence of debt is a genuine comfort, but I need evidence of margin stabilization and profit recovery before committing new capital. Price alone is not enough.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer